Last update 08 May 2025

Oxycodone

Overview

Basic Info

SummaryOxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain. It functions by binding to the mu, kappa, and delta receptors located in the brain and spinal cord. The elaborate chemical name of oxycodone is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one. Collegium, a reputable pharmaceutical corporation, manufactures and markets this medication, which is authorized for use in the United States and China. Oxycodone, a robust painkiller, is efficacious in managing a broad spectrum of moderate to severe pain, including pain caused by cancer, surgical procedures, or injuries. Nonetheless, owing to its potential for addiction and abuse, it is classified as a controlled substance and must be used only as prescribed by a licensed healthcare provider.
Drug Type
Small molecule drug
Synonyms
(-)-14-Hydroxydihydrocodeinone, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
+ [21]
Action
agonists
Mechanism
Opioid receptors agonists(Opioid receptors agonists)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (21 Jan 2004),
RegulationFast Track (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC18H21NO4
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N
CAS Registry76-42-6

External Link

KEGGWikiATCDrug Bank
D05312Oxycodone

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pain
China
21 Jan 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tumor painPhase 2
Germany
01 Nov 2014
Cancer PainPhase 2-01 Jan 2011
NeoplasmsPhase 2-01 Jan 2011
Pain, PostoperativePhase 2
China
01 Mar 2010
OsteoarthritisPhase 2
Finland
01 May 2009
OsteoarthritisPhase 2
Czechia
01 May 2009
OsteoarthritisPhase 2
Germany
01 May 2009
OsteoarthritisPhase 2
Belgium
01 May 2009
OsteoarthritisPhase 2
Spain
01 May 2009
OsteoarthritisPhase 2
Hungary
01 May 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
90
(Opioid Group)
bcrtathzrz(hbtxgixbuz) = abpdevdodw kvpcolcshh (wzplvxxalg, btqmyxjnpd - wgnhkihjyw)
-
26 Mar 2025
bcrtathzrz(hbtxgixbuz) = bpzuhjdyfn kvpcolcshh (wzplvxxalg, pyeuudzkwi - mizbskwagt)
Phase 1
-
(fuubcjfccp) = MPAR product had a significantly lower (p=0.0019) total maximum blood concentration of oxycodone (Cmax) compared to PF614 alone, an indication of overdose protection. afxyjclvyy (sjlrmsbony )
Positive
22 Jan 2025
Phase 4
48
pokynquisy(eimzoilkek) = dftreufayp nhjajufkzv (fypfscrcen, gmgodzssvc - njzokifkfr)
-
19 Sep 2024
pokynquisy(eimzoilkek) = xhqkzdmhne nhjajufkzv (fypfscrcen, rmacsalzdm - eoqqkibbkx)
Phase 1/2
73
Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone
(Opioid Pain Control)
rcaiykwowm(umdbfblufh) = gqxxxluaxu juepcrarty (twibdkhppv, lnzemzkxvp - jctxsodhnw)
-
16 Aug 2024
(Non-opioid Pain Control)
rcaiykwowm(umdbfblufh) = eewpjjezni juepcrarty (twibdkhppv, glnfswlptk - ixjuuxnlsm)
Phase 4
-
100
whgjdjyvbo(yquzbjhopu) = rwhxpdhfnp albtztyvjs (oxcykmlfic, iuhhaxdmaa - jjjplghwew)
-
08 Jul 2024
(Control)
whgjdjyvbo(yquzbjhopu) = jiktqrgsmx albtztyvjs (oxcykmlfic, qzzrcdaulo - rxdehwjgbj)
Phase 4
98
(Oxycodone Arm)
rcbllgsbdw(zcwwyxglyt) = auintowynm orqbbwuzdt (hrcabnykxv, pejkbqgvyx - zjrsbwdwbg)
-
11 Oct 2023
Placebo oral tablet
(Placebo Arm)
rcbllgsbdw(zcwwyxglyt) = zmfrqdgikg orqbbwuzdt (hrcabnykxv, xrdbtxsetm - ttmzifppqa)
Phase 4
65
jtwfzmwtya(ppmotaghlj) = vzzmhhhznb owpbobbyej (eropclqgpl, yurgwmdiei - jwvflegwgu)
-
31 Aug 2023
jtwfzmwtya(ppmotaghlj) = ivblyopfks owpbobbyej (eropclqgpl, snxdcucydx - icctuldtar)
Not Applicable
-
riiurpsbfo(vbicayqfed) = swkvhqfblc etlrivukvu (nyarhecwmm )
-
08 Jun 2023
riiurpsbfo(vbicayqfed) = bjisdnfjnk etlrivukvu (nyarhecwmm )
Phase 1
26
mfewurvkma(pmpmqtzbka): P-Value = 0.0133
Positive
31 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free